Genmab Reports 50% Lower Death Risk in Phase 3 Trial

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

COPENHAGEN, Denmark--(BUSINESS WIRE)--Oct 26, 2026-

Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%

The Phase 3 data involved certain patients with head and neck cancer. Petosemtamab is a bispecific antibody therapy.

Genmab reports 50% lower death risk in Phase 3 trial

Genmab's petosemtamab combination reduced death risk by 50 per cent versus pembrolizumab alone in a Phase 3 head-and-neck cancer trial.

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer